These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8480847)

  • 21. [The relevance of dopamine agonists in the treatment of depression].
    Clausius N; Born C; Grunze H
    Neuropsychiatr; 2009; 23(1):15-25. PubMed ID: 19272288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
    Cheshire PA; Williams DR
    J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotonin, dopamine, and motor effects in Parkinson's disease.
    Miyawaki E; Meah Y; Koller WC
    Clin Neuropharmacol; 1997 Aug; 20(4):300-10. PubMed ID: 9260728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current approaches in the treatment of Parkinson disease].
    Caraceni T; Geminiani G; Tamma F
    Recenti Prog Med; 1989 Dec; 80(12):686-91. PubMed ID: 2576471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depression in Parkinson's disease -- a review.
    Lieberman A
    Acta Neurol Scand; 2006 Jan; 113(1):1-8. PubMed ID: 16367891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-Dopa and the treatment of extrapyramidal disease.
    Pelton EW; Chase TN
    Adv Pharmacol Chemother; 1975; 13():253-304. PubMed ID: 1106161
    [No Abstract]   [Full Text] [Related]  

  • 28. Current views on Parkinson's disease.
    Calne DB
    Can J Neurol Sci; 1983 Feb; 10(1):11-5. PubMed ID: 6132677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The currently accepted pathophysiological model underlying surgical management of Parkinson disease].
    Sobstyl M; Zabek M; Koziara H
    Neurol Neurochir Pol; 2003; 37(1):203-13. PubMed ID: 12910841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Parkinson's disease: some physiopathologic aspects and clinical practice].
    Agid Y
    Rev Prat; 1989 Mar; 39(8):641-6. PubMed ID: 2567050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 33. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.
    Montastruc JL; Fabre N; Blin O; Senard JM; Rascol O; Rascol A
    Mov Disord; 1995 May; 10(3):355-7. PubMed ID: 7651460
    [No Abstract]   [Full Text] [Related]  

  • 34. Letter: Extrapyramidal dementia and levodopa.
    Drachman DA; Stahl S
    Lancet; 1975 Apr; 1(7910):809. PubMed ID: 48039
    [No Abstract]   [Full Text] [Related]  

  • 35. Does fluoxetine exacerbate Parkinson's disease?
    Caley CF; Friedman JH
    J Clin Psychiatry; 1992 Aug; 53(8):278-82. PubMed ID: 1500404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding Parkinson's disease.
    Youdim MB; Riederer P
    Sci Am; 1997 Jan; 276(1):52-9. PubMed ID: 8972618
    [No Abstract]   [Full Text] [Related]  

  • 37. Parkinson's disease.
    Clarke C; Moore A
    Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
    [No Abstract]   [Full Text] [Related]  

  • 38. Fluoxetine and extrapyramidal side effects.
    Am J Psychiatry; 1989 Oct; 146(10):1352-3. PubMed ID: 2604792
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.